TBI-302 (Therapure Biopharma)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameTBI-302 (Therapure Biopharma)
Drug Alias NameTBI-302
ClassificationBiologics
Mechanisms of ActionThymidylate synthase inhibitors
TargetsThymidylate synthase
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTherapure Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTherapure Biopharma Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A